NCT02261519 — "Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophrenia in Adults" trial site landscape

Public-registry site landscape for NCT02261519, “Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophrenia in Adults”, a Schizophrenia study sponsored by SyneuRx International (Taiwan) Corp. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT02261519 (registry record)
Study title	Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophrenia in Adults
Official title	An Adaptive, Phase IIb/III, Multi-center, Prospective, Randomized, Double-Blind Placebo-controlled Study of the Safety and Efficacy of NaBen® (DAAO Inhibitor), as an Add-on Treatment for Schizophrenia in Adults
Sponsor	SyneuRx International (Taiwan) Corp
Condition(s)	Schizophrenia
Phase	PHASE2 / PHASE3
Listed sites	1
Site countries	United States

Patient-friendly overview of this study: eichor.com/study/NCT02261519.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT02261519 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Related trials

Other Schizophrenia trials

← Eichor home · All tracked trials · Schizophrenia studies · Weekly briefs

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →